Given that all of these mutations converge on mTORC1 leading to its hyperactivation, pharmacological intervention with mTOR inhibitors (e.g., rapamycin and its analog everolimus) has been proposed as a therapeutic option for epilepsy associated with these MCDs. Here, MTOR is linked to epilepsy.